Gabapentinoid Use in the United States 2002 Through 2015

Michael E Johansen, Michael E Johansen

Abstract

This cohort study uses 2002-2015 Medical Expenditure Panel Survey data to characterize the use of gabapentinoids among the US adult population.

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.. Gabapentinoid Use in the United… — Figure 1.. Gabapentinoid Use in the United States, 2002 Through 2015
The figure identifies the proportion of adults (>17 years) who reported a filled prescription for gabapentin, pregabalin, or a gabapentinoid during a calendar year between 2002 and 2015.

Figure 2.. Gabapentinoid Use by Subgroups, 2002… — Figure 2.. Gabapentinoid Use by Subgroups, 2002 Through 2015
The figure identifies the proportion of gabapentinoid users among adults stratified by age (

See this image and copyright information in PMC

References

1. Kesselheim AS, Darby D, Studdert DM, Glynn R, Levin R, Avorn J. False Claims Act prosecution did not deter off-label drug use in the case of neurontin. Health Aff (Millwood). 2011;30(12):2318-2327.
1. Shanthanna H, Gilron I, Rajarathinam M, et al. . Benefits and safety of gabapentinoids in chronic low back pain: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2017;14(8):e1002369.
1. Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28(6):491-496.
1. Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14(10):e1002396.
1. Mathieson S, Maher CG, McLachlan AJ, et al. . Trial of pregabalin for acute and chronic sciatica. N Engl J Med. 2017;376(12):1111-1120.
1. Agency for Healthcare Research and Quality (AHRQ), Center for Financing, Access, and Cost Trends MEPS HC-181: 2015 Full Year Consolidated Data File. . Published August 2017. Accessed September 18, 2017.

Source: PubMed

3

Iratkozz fel